Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The *Plasmodium falciparum liver stage* is the first stage of infection in humans, during which sporozoites infect hepatocytes, undergo extensive replication, and mature into thousands of merozoites that eventually infect red blood cells, leading to clinical malaria. This stage is asymptomatic but is a bottleneck and thus a promising target for vaccines and chemoprophylaxis. Key antigens and molecular complexes involved include CSP, LISP1, LISP2, EXP2, and the PTEX translocon, all of which are considered molecular targets within the broader "liver stage" context
Inhibition of *Plasmodium* development or survival in hepatocytes (e.g., disrupting mitochondrial function, interfering with metabolic pathways, causing parasite death before it reaches blood stage)
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Plasmodium falciparum liver stage (null).